- FDA will conduct more review of Eli Lilly’s Alzheimer’s drug donanemab – The Washington Post The Washington Post
- U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab | Eli Lilly and Company Investors | Eli Lilly and Company
- F.D.A. Delays Action on Closely Watched Alzheimer’s Drug The New York Times
- Eli Lilly’s donanemab Alzheimer’s drug delayed by FDA USA TODAY
- Eli Lilly Alzheimer’s Drug Delayed as FDA Plans Advisory Panel Meeting The Wall Street Journal
You can read the full story here: “Eli Lilly’s Alzheimer’s Drug Faces Unexpected FDA Review, Delaying Approval” .